|
 |
| home > epc > winter 2003 > bridging studies - what questions should be asked in phase i clinical research? |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
Inter-ethnic, head-to-head, pharmacovariance or bridging: although they may sound very different, essentially these types of study have the same objective - to provide integrated clinical data towards a new ethnic region regulatory dossier, thus allowing the extrapolation of foreign clinical data for regulatory submission - to bridge the gap between data obtained in distinct ethnic regions. Japan does not have access to some latter generation drugs, which offer marked therapeutic advantages, because the high development costs are generally not justified by the potential market size (1).
Consequently, patients rely on more dated treatments. The desire to extend the market value of a licensed drug to closed regions like Japan ensures that the industry is effectively reaching a previously untapped market at a reasonable cost. In order to redress this balance, Japan, the EU and the US independently proposed regulations to increase the acceptability of foreign data in support of market licences, back in the 1980s.
These independent regulations were brought together in the 1990s by the E5 Expert Working Group of the International Conference on Harmonisation (ICH). The purpose of ICH E5 (Guideline on Ethnic Factors) (2) is to expedite the global development and availability of new medicinal products without impacting established safeguards relating to quality, safety and efficacy between ethnic populations. Assuming that regulatory requirements for the new region are met, bridging data is required to investigate the possibility of ethnic difference between populations in distinct geographical regions. The need for bridging foreign data requires that the following is considered:
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
“PACK DIFFERENT” with EMBALLAGE 2008
“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >> |
|
 |
